The 22nd Medlab Middle East was held grandly at the Dubai World Trade Center in UAE from February 6 to 9, 2023. This exhibition showcases many new products in the global medical field, attracting more than 700 medical companies from more than 40 countries and regions, and more than 20,000 professionals attending the exhibition. 

Dynamiker made a wonderful appearance with the world's first POCT diagnostic solution for invasive fungal diseases and the latest product series. The pet diagnostic series products exhibited overseas for the first time attracted many distributors to stop and learn about them. And the latest developed bacterial resistance products have also received a lot of attention and recognition.

Diagnosis is one step faster, prognosis is very different

Since the company launched the POCT detection platform for invasive fungal diseases in 2022, the product has been highly praised for its advantages such as "fast results, LIS link, automatic printing, and all-in-one diagnosis." During the exhibition, many customers came to consult and expressed that this product can be widely used in clinical settings such as laboratory departments, emergency departments, and ICUs. The POCT diagnostic solution for invasive fungal diseases has been recognized and affirmed by customers.

Pet diagnostic products debut to protect pet health

At the same time, Dynamiker launched its independently developed pet rapid test (fluorescence immunochromatography and colloidal gold method) for the first time overseas. A customer from Egypt said: "I once had pets, and pets are like our family. I hope that all pets can be diagnosed in time and regain their health. I have great expectations for your new products!"

To curb bacterial resistance, Dana Biotechnology is taking action

WHO has been calling on countries to pay attention to the issue of microbial resistance for many years. This year, Dynamiker launched a drug-resistant bacteria detection platform - ERIC™ Carbapenemase Detection Kit (colloidal gold method) to actively respond to microbial resistance challenges and better protect people’s health. The feature of identifying 5 carbapenemase types (KPC/NDM/IMP/OXA-48/VIM) with one card makes the product favored by customers.

Dynamiker will continue to speak out in the IVD industry, continue to innovate and make breakthroughs, contribute to the diagnosis of pathogenic microorganisms, and make new contributions to the great health cause at home and abroad!